Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(33.3%)
N/A
1(33.3%)
Phase 4
1(33.3%)
3Total
Phase 2(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04145674Phase 2Suspended

A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo

Role: lead

NCT03196583Not ApplicableCompleted

Efficacy of a Novel MAD in OSA

Role: lead

NCT02025608Phase 4Completed

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome

Role: lead

All 3 trials loaded